Compare · Mevaco, Unibios, Doppler
Share prices with dividends, events and key figures
MEVAMevacoFocusBIOSKUnibiosDOPPLERDoppler
Trend · vs peers
Mevaco: -28.4% against a peer median of -18.8%, 9.6 points apart
% since 24/10/2025, dividends included
Show
Coming up
| Return · 1Y | |
|---|---|
| Doppler · DOPPLER | −9.8% |
| Unibios · BIOSK | −27.7% |
| Mevaco · MEVA | −28.4% |
Athens Stock Exchange closes, adjusted for dividends · xrimatistirio
Ask MENTOR about this comparison
Key figures
| MEVA | BIOSKlike-for-like | DOPPLERlike-for-like | Peer median2 counted | ||
|---|---|---|---|---|---|
| Price | |||||
| Price | €5.74 | €2.06 | €0.654 | ||
| Return, 1Y | −28.4% | −27.7% | −9.8% | −18.8% | |
| From its 52-week high | −41.7% | −37.6% | −34.6% | −36.1% | |
| Size and growth | |||||
| Market value | €60.3m | €35.3m | €8.2m | ||
| Revenue, last 12 months | €41.1m | €15.2m | €21.2m | ||
| Revenue growth, latest year | +19.6% | −5.6% | +22.1% | +8.3% | |
| Latest results: revenue | −64.1%H1 2026 | +19.9%H1 2026 | — | ||
| Profitability | |||||
| EBITDA margin | 16.1% | 17.0% | 8.7% | 12.9% | |
| Net margin | 10.3% | 10.7% | 1.3% | 6.0% | |
| Return on equity | 10.5% | 8.3% | — | ||
| Balance sheet | |||||
| Net debt | −€5.4m | €4.0m | €10.9m | ||
| Net debt / EBITDA | -0.8× | 1.5× | 5.9× | 3.7× | |
| Valuation | |||||
| EV/EBITDAthe measure for this business | 8.3× | 16× | 10× | 13× | |
| P/E | 14× | 24× | — | ||
| P/B | 1.5× | 1.9× | — | ||
| Shareholder returns | |||||
| Dividend yield | 4.4% | 0.0% | 0.0% | 0.0% | |
Price
MEVA€5.74
BIOSK€2.06
DOPPLER€0.654
Return, 1YPeer median −18.8%
MEVA−28.4%
BIOSK−27.7%
DOPPLER−9.8%
From its 52-week highPeer median −36.1%
MEVA−41.7%
BIOSK−37.6%
DOPPLER−34.6%
Peer median: the companies ticked (like-for-like ones to start with). A flagged figure is left out and shown faint; hover for the reason. It needs two figures, one for a return.
Valuation, margins and debt: latest reported twelve months · growth: company reports, from the reviewed dossiers · latest results: exchange announcements
Five years
- Mevaco
- Unibios
- Doppler
Revenue
2021 = 100
EBITDA margin
%
Net margin
%
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue · MEVA | €25.6m | €41.0m | €43.0m | €60.8m | €72.7m |
| Revenue · BIOSK | €8.5m | €11.2m | €13.0m | €14.7m | €13.9m |
| Revenue · DOPPLER | €16.4m | €17.6m | €18.5m | €17.3m | €21.2m |
| EBITDA · MEVA | €3.4m | €5.0m | €4.9m | €7.7m | €14.1m |
| EBITDA · BIOSK | €1.3m | €1.8m | €3.4m | €2.7m | €3.2m |
| EBITDA · DOPPLER | €1.2m | €1.6m | €1.6m | €1.3m | €1.9m |
| Net income · MEVA | €1.9m | €3.2m | €3.2m | €5.0m | €10.1m |
| Net income · BIOSK | €0.3m | €0.7m | €2.0m | €1.0m | €1.7m |
| Net income · DOPPLER | €-0.5m | €-0.1m | €-1.1m | €-0.5m | €0.3m |
Company annual reports, from the reviewed dossiers · to 16/10/2026